Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958309 | 0.80 | P2RX7 (0.62) | P2RX7GRM5RAB9AMAPTNPC1 | |
| SCHEMBL7438583 | 0.76 | P2RX7 (0.44) | P2RX7GRM5RAB9AMAPTCYP1A2 | |
| SCHEMBL17500313 | 0.75 | CNR2 (0.63) | CCND3CDK6RAB9AMAPTKDM4E | |
| SCHEMBL11454469 | 0.75 | CNR2 (0.58) | P2RX7GRM5RAB9AMAPTNPC1 | |
| SCHEMBL9787409 | 0.75 | P2RX7 (0.43) | P2RX7GRM5RAB9ANPC1KDM4E | |
| SCHEMBL371069 | 0.73 | TSHR (0.54) | CCND3CDK6RAB9ANPC1KDM4E | |
| SCHEMBL22061926 | 0.73 | P2RX7 (0.55) | P2RX7GRM5RAB9ANPC1KDM4E | |
| SCHEMBL2237588 | 0.72 | P2RX7 (0.62) | P2RX7GRM5RAB9AMAPTNPC1 | |
| SCHEMBL23366592 | 0.71 | CNR2 (0.59) | P2RX7GRM5RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5655094 | 0.71 | HSD17B14 (0.49) | P2RX7GRM5RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | P2RX7 4223/4885GRM5 3101/4885CCND3 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.